Dr. Femida Gwadry‐Sridhar is the Founder and CEO of Pulse Infoframe Inc. She has her PhD in Health Research Methodology, Health Economics, McMaster University. She is a pharmacist, clinical epidemiologist and methodologist with over 25 years of experience in clinical trials, disease registries, knowledge translation, health analytics and patient reported outcome measures. Pulse Infoframe has developed healthieTM.Pulse implements appropriate governance in advance of building multi-stakeholder collaborative networks of pharmaceutical companies, researchers and patients and enables stakeholder access to clinical trials, input on trial design, new treatment development, and accelerated research.
Clinical Dx Showcase:
Pulse Infoframe Inc.
Deployed globally and focused on cancer and rare disease, Pulse Infoframe (Pulse) is a real-world evidence health informatics and analytics company that has created a technology and services platform empowering a consortia of stakeholders - including patients, advocates, caregivers, physicians, researchers, pharmaceutical & medical device companies.
Unlocking the Power of AI - Real-World Evidence Informing Precision Medicine
Evidenced-based approaches to investigating new therapies are the cornerstone of advancing clinical practice. Given the advances in genotyping and molecular profiling there are greater opportunities to understand the biology of a disease. However, part of the consideration when implementing new therapies is an understanding of the impact of the treatment in patients who are not part of a clinical trial in order to understand how treatment can adversely or positively affect patient safety, outcomes, performance measures and costs. The primary obstacles to realizing the benefits of new treatments and achieving reduced variation post-approval, center around the limited availability of real-world data.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.